XPO Named a 2024 Top Company for Women to Work in Transportation by Women in Trucking
GREENWICH, Conn., Nov. 13, 2024 (GLOBE NEWSWIRE) — XPO (NYSE: XPO), a leading provider of freight transportation in North America, has […]
CleanCore Solutions, Inc. (ZONE) Reports First Quarter FY 2025 Financial Results and Provides Business Update
Omaha, NE, Nov. 13, 2024 (GLOBE NEWSWIRE) — CleanCore Solutions, Inc. (NYSE American: ZONE) (“CleanCore” or the “Company”), developer of […]
Healthy Choice Wellness Provides Shareholder Update Highlighting Positive Financial and Operational Improvements
HOLLYWOOD, FL, Nov. 13, 2024 (GLOBE NEWSWIRE) — Healthy Choice Wellness Corp. (“HCWC” or the “Company”) (NYSEAM: HCWC), a holding […]
Auto Insurance Shopping Increased 19% Year over Year in Q3 2024
CHICAGO, Nov. 13, 2024 (GLOBE NEWSWIRE) — The third quarter of 2024 saw a big spike in shopping for both […]
Pineapple Financial, Inc. Announces Pricing of $1.0 Million Registered Direct Offering
Toronto, Nov. 13, 2024 (GLOBE NEWSWIRE) — Pineapple Financial, Inc. (NYSE: PAPL) (the “Company”), Canada’s tech-focused mortgage brokerage with an […]
Dayforce Announces Dayforce Strategic Workforce Planning
MINNEAPOLIS and TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management […]
Dayforce Introduces Dayforce Communications
MINNEAPOLIS and TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management […]
Dayforce Announces Dayforce AI Agents
MINNEAPOLIS and TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) — Dayforce, Inc. (NYSE: DAY; TSX: DAY), a global human capital management […]
Mark Karns Joins Ingredion as VP Corporate Development and M&A
WESTCHESTER, Ill., Nov. 13, 2024 (GLOBE NEWSWIRE) — Ingredion Incorporated (NYSE: INGR), a leading global provider of ingredient solutions to the […]
Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del tercer trimestre de 2024
Logro del objetivo de inscripción de 92 pacientes evaluables en VIRAGE, el ensayo clínico de Fase 2b de VCN-01 en […]
